Free Trial
NASDAQ:HRMY

Harmony Biosciences Q1 2025 Earnings Report

Harmony Biosciences logo
$30.32 +0.46 (+1.54%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$30.86 +0.54 (+1.78%)
As of 05/2/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
$0.59
Beat/Miss
N/A
One Year Ago EPS
N/A

Harmony Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$184.26 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Harmony Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Harmony Biosciences Earnings Headlines

Q1 EPS Forecast for Harmony Biosciences Lowered by Analyst
REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.
Harmony Biosciences price target lowered to $32 from $33 at BofA
See More Harmony Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harmony Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harmony Biosciences and other key companies, straight to your email.

About Harmony Biosciences

Harmony Biosciences (NASDAQ:HRMY), a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

View Harmony Biosciences Profile

More Earnings Resources from MarketBeat